BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL). Results of prospective clinical trials demonstrate the efficacy of venetoclax to salvage patients with disease progression on BTKis, but data on B...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Lin, Victor S., Lew, Thomas E., Handunnetti, Sasanka M., Blombery, Piers, Nguyen, Tamia, Westerman, David A., Kuss, Bryone J., Tam, Constantine S., Roberts, Andrew W., Seymour, John F., Anderson, Mary Ann
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2020
Onderwerpen:
Lymphoid Neoplasia
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7316215/
https://ncbi.nlm.nih.gov/pubmed/32244251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020004782
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items